Microba Life Sciences Ltd received a $6.08 million R&D Tax Incentive refund from the Australian Government for eligible R&D activities conducted in the 2022/2023 financial year, aimed at supporting their development of therapeutics and diagnostic tests for gastrointestinal conditions.
Additionally, the company secured four Advanced Overseas Findings from AusIndustry, pre-approving eligible overseas expenditure for R&D activities in their Inflammatory Bowel Disease and Autoimmune Diseases therapeutic programs across four fiscal years.
ASX Code: MAP